BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tykerb: Completed Phase III enrollment

GlaxoSmithKline completed enrollment in the open-label, Asian Phase III TyTAN trial comparing Tykerb plus paclitaxel vs. paclitaxel alone in about 314 patients. The first part of TyTAN is designed to find the optimal dose...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >